May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Expert Investigators Discuss Emerging Therapies for GI Cancers
February 11th 2015A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.
Read More
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
January 28th 2015Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Read More
Potential Predictive and Prognostic Biomarkers for Ziv-Aflibercept Treatment Identified
January 20th 2015Interim results reported from a retrospective study of plasma samples from the VELOUR trial reveal multiple potential prognostic and predictive biomarkers to guide treatment of patients with mCRC with the VEGF-inhibitor ziv-aflibercept.
Read More
'Watch and Wait' Approach May Lead to Excellent Outcomes in Rectal Cancer
January 14th 2015A “watch and wait†surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery. This retrospective review of clinical data was presented at the 2015 Gastrointestinal Cancers Symposium.
Read More
Vitamin D Improves Outcomes in Patients With mCRC
January 13th 2015Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment. This research was reported at a press briefing in advance of the 2015 Gastrointestinal Cancers Symposium.
Read More
The Management of Treatment-Related AEs in Advanced CRC
November 12th 2014As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.
Read More
TAS-102 Receives Fast Track Designation for mCRC
October 21st 2014TAS-102 (tipiracil hydrochloride) has received a fast track designation from the FDA as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the US.
Read More
An Analysis of Bevacizumab or Cetuximab for CRC
August 13th 2014Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).
Read More
Significant OS Benefit Seen With TAS-102 Monotherapy in Refractory mCRC
August 13th 2014Significantly extended overall survival (OS) and progression-free survival (PFS) was seen with oral nucleoside TAS-102 treatment in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Read More
Survival Benefit Confirmed With Palliative Resection in mCRC
August 13th 2014Palliative care involving initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit in patients with mCRC compared with the same treatments administered in the reverse order.
Read More
First DNA-Based CRC Screening Tool Approved
August 12th 2014The FDA has approved Cologuard as the first noninvasive stool-based DNA test for the detection of CRC in asymptomatic individuals at average risk, based on clinical trial results demonstrating superiority to the fecal immunochemical test.
Read More
Active Maintenance With or Without Bevacizumab Improves PFS in mCRC
July 21st 2014Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer (mCRC).
Read More
Targeting Radiotherapy in the Liver: SIR-Spheres®
June 23rd 2014The liver is a common site of metastatic recurrence for many tumors. For a minority of patients, surgical resection may be an option; however, most patients will not qualify for surgery due to insufficient liver functional reserve or other contraindications.
Read More